Brolucizumab 相關新聞

← 返回新聞總覽

---

Brolucizumab 目前有 0 則相關新聞報導，預測適應症 10 個。

本頁整合 Brolucizumab 的 AI 預測適應症與最新健康新聞，橘色標示的適應症表示近期有相關新聞報導。

藥物資訊

• 原適應症：Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).
• 證據等級：L5
• 預測適應症（10 個）：
  • Mitochondrial oxidative phosphorylation disorder (nuclear DNA) | 99.67% | Extremely low — no known VEGF role in mitochondrial respiratory chain | ✗（99.0%）
  • Esophageal varices without bleeding | 99.12% | Low — systemic anti-VEGF rationale theoretically exists, but intravitreal route cannot reach portal vasculature | ✗（99.0%）
  • Esophageal varices with bleeding | 99.12% | Low — same as above; acute hemorrhage context makes this additionally unsafe | ✗（99.0%）
  • Exocrine pancreatic insufficiency | 99.07% | None — VEGF-A has no established role in exocrine enzyme secretion | ✗（99.0%）
  • MRCS syndrome | 98.54% | Very low — retinal component present, but atrophic rather than neovascular; no VEGF driver | Partial（99.0%）
  • Pigmented paravenous retinochoroidal atrophy (PPRA) | 98.33% | Low-moderate — same ocular tissue and delivery route; VEGF overexpression not established in PPRA | ✓（99.0%）
  • Familial flecked retinopathy | 97.90% | Low — genetic/degenerative photoreceptor disease (e.g., ABCA4 mutations), not neovascular | ✓（99.0%）
  • Ectopia lentis-chorioretinal dystrophy-myopia syndrome | 97.82% | Moderate if choroidal neovascularization (CNV) is present — myopic CNV is an established anti-VEGF target | ✓（99.0%）
  • Retinal dystrophy in systemic or cerebroretinal lipidoses | 97.73% | Very low — lysosomal storage disorder; retinal degeneration is secondary and VEGF-independent | ✓（99.0%）
  • Senile reticular retinal degeneration | 97.71% | Moderate — AMD-related phenotype (reticular pseudodrusen); closest to the approved indication; however, if purely dry-form, anti-VEGF benefit is unproven | ✓（99.0%）

查看完整藥物報告 →

相關新聞（0 則）

目前沒有相關新聞報導。當有新聞提到此藥物時，系統會自動收集並顯示在這裡。

免責聲明：本頁新聞由系統自動收集，僅供研究參考，不構成醫療建議。